Problem & solution

$5-7 billion wasted on inhaler misuse every year.

Of an estimated $25 billion spent on inhalers annually, $5-7 billion is wasted because patients use their inhalers incorrectly. Poor inhaler technique also means poor symptom control, emergency visits and hospitalizations. Kata was built to change it.

The problem

Respiratory disease has a massive public health impact.

80M

people living with respiratory disease in the US and EU, including asthma and COPD

3.4M

deaths worldwide from COPD in 2023, the third leading cause of death (WHO)

Inhaled therapies are the backbone of treatment. New therapies keep emerging, yet inhaler devices have changed little over the years.

Photo: Marcus Gloger MedCom: UK

Inhaler technique is often incorrect and difficult to address in real life.

90%

of patients do not perform their inhalation therapy correctly.

50%

increased risk of hospitalization with poor inhaler technique.

Difficult to address in real life

Would require a clinician to watch every inhalation.
Patients may not know they are making mistakes.

Our solution: Kata

AI technology that enhances inhaled therapies.

Better inhalation quality. Better clinical outcomes.

Our solution

Kata

AI-powered inhaler coach that guides, monitors and coaches at each inhalation.

Analyzes inhalation technique using AI and sound + video recognition.
Provides real-time, personalized coaching and feedback.
Monitors usage and technique over time.

Up to 100%reduction in critical device-handling errors

Broad scalability

Works with >95% of inhaler devices.

MDI
DPI
SMI
Other

Compatible with >95% of inhaler devices (MDI, DPI, SMI).
Requires only a smartphone, no additional hardware.
Enables rapid deployment across health systems.

KATA

The AI-powered inhaler coach

Better technique
+
Greater adherence
+
Improved outcomes

Healthier lungs. Brighter futures.

Sources

Where these figures come from.

World Health Organization. Chronic obstructive pulmonary disease (COPD), fact sheet, 10 June 2026. who.int
Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people with asthma. Cochrane Database Syst Rev. 2017;3:CD012286.
Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care. 2005;50(10):1360-1374.
Roggeri A, Micheletto C, Roggeri DP. Inhalation errors due to device switch in patients. Int J Chron Obstruct Pulmon Dis. 2016;11:597-602.
Grand View Research, 2022. US inhalable drugs market estimate (About Us page).
Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019 Mar 14;15:461 -472.
WHO respiratory diseases reporting and further clinical studies cited by Synvero Health.
Häußermann S, Arendsen LJ, Pritchard JN. Smart dry powder inhalers and intelligent adherence management. Adv Drug Deliv Rev. 2022;191:114580. doi:10.1016/j.addr.2022.114580
Arendsen L, Beeh K, Kroneberg P, Meyer M, Wencker M. The use of a digital inhalation coach reduces inhalation errors in a clinical trial. Poster presented at: European Respiratory Society (ERS) International Congress; September 7-11, 2024; Vienna, Austria.
Kroneberg P, Arendsen LJ, Beeh KM, Häußermann S, Meyer M, Wencker M. The use of a digital inhalation coach in a clinical trial to ensure high inhaled medication adherence and improve inhalation technique. Poster presented at: American Thoracic Society (ATS) International Conference; May 16-21, 2025; San Francisco, CA.
Trinkmann F, Arendsen L, Meyer M, Kroneberg P, Häußermann S, Herth FJF, et al. Improving inhaler technique through digital feedback: KaRe randomized controlled trial of a digital inhalation coach in asthma patients. Am J Respir Crit Care Med. 2026;212(suppl 1):aamag162.436. doi:10.1093/ajrccm/aamag162.436.
Trinkmann F, Arendsen L, Meyer M, Kroneberg P, Häußermann S, Herth FJF, et al. Self-reported adherence substantially overestimates objectively measured inhaler use: findings from KaRe randomized controlled trial of a digital inhalation coach in asthma patients. Am J Respir Crit Care Med. 2026;212(suppl 1):aamag162.678. doi:10.1093/ajrccm/aamag162.678.

Work with us

Partner with Synvero.

We are preparing our US market entry through commercial partnership with payers, health networks and providers who treat patients with respiratory diseases. Health care professionals, payers and investors: we’d like to engage with you.